MedPath

SWISS BIOPHARMA MED GmbH

Ownership
Private
Employees
-
Market Cap
-
Website

Clinical Trials

1

Active:0
Completed:1

Trial Phases

1 Phases

Early Phase 1:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials

Early Phase 1
1 (100.0%)

Phase 0/1 Local Application of the Monoclonal Antibody (Mab) sB24M in Patients With Purulent Pyoderma

Early Phase 1
Completed
Conditions
Pyoderma Gangrenosum
Pyoderma Vegetans
Pyoderma
Pyoderma Gangrenosum Surrounding Surgical Stoma
First Posted Date
2021-05-20
Last Posted Date
2023-03-20
Lead Sponsor
SWISS BIOPHARMA MED GmbH
Target Recruit Count
10
Registration Number
NCT04895566
Locations
🇱🇻

Contract Research Organization, Rīga, Latvia

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.